endpts.com·Jun 1, 2026
Eli Lilly has entered the GLP-2 market by signing a licensing deal with South Korea's Hanmi Biopharma for $75 million upfront, expanding its portfolio following the success of its GLP-1 drugs. Additionally, Lilly has established a discovery partnership with China's Haisco.
The most valuable insight for you is that Eli Lilly is expanding its portfolio in the GLP-2 space through a licensing deal with Korean biotech Hanmi, indicating a strategic move to diversify beyond its successful GLP-1 drugs. This suggests a potential area for investment or partnership opportunities in the GLP-2 market, reflecting growing interest and potential in this segment of biopharma.